Life Sciences Venture Fund

Life sciences are a strategic pillar of Canada’s economic resilience, public health, and long-term competitiveness, yet remain underfunded despite strong performance and global potential. BDC’s $150 million Life Sciences Venture Fund is designed to strengthen Canada’s life sciences ecosystem by addressing critical capital gaps throughout a company's growth journey.

Investing where it matters

We primarily support businesses from seed to early-stage investment. The fund focuses on two areas where funding gaps are most significant: 

• Therapeutic Products
  Biotechnology‑based innovations such as laboratory‑developed proteins and antibodies, gene and cell therapies, and medicines based on nucleic acids.
• Medical Technologies
  Medical devices, diagnostic tools, imaging technologies, surgical robotics, and related clinical software used to diagnose, treat or monitor health conditions.

By leveraging direct investments and complementing existing market players, the fund aims to accelerate commercialization, attract private capital, and enable Canadian life sciences companies to scale into global leaders.

If you are interested in learning more, contact us.